SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324

Go back to SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 215.50 -3.55 (1.62%)
Previous Close $219.05    52 Week High $333.65 
Open $219.05    52 Week Low $223.02 
Day High $220.17    P/E 27.59 
Day Low $215.26    EPS $7.81 
Volume 2,635,886       

Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 933,248       

Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 933,248